Dalteparin alternative in VTE prevention for patients with cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.506, 2006-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dalteparin alternative in VTE prevention for patients with cancer

Inpharma, Vol. 1, Iss. 1545, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

New guidelines for VTE prevention/treatment in cancer patients

Inpharma, Vol. 1, Iss. 1616, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

New guidelines for VTE prevention/treatment in cancer patients

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 542, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients: A Pharmacoeconomic Analysis

By Dranitsaris George

PharmacoEconomics, Vol. 24, Iss. 6, 2006-01 ,pp. : 593-607

Adis International

Access to resources Recommend Favorite

Dalteparin cost effective for VTE prophylaxis in the US?

Inpharma, Vol. 1, Iss. 1508, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite